Lars Agréus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lars Agréus has a total of 253 co-authors. Here are the top co-authors by number of shared publications:
Nicholas J. Talley
20 shared publications- Anna Andreasson
Stress Research Institute, Department of Psychology, Stockholm University, Stockholm, Sweden
19 shared publications - Jukka Ronkainen
Primary Health Care Center, Tornio, Finland
14 shared publications - Pertti Aro
Centre for Family Medicine, Karolinska Institutet, Stockholm, Sweden
13 shared publications - Marjorie M. Walker
Department of Histopathology, Imperial College London, St Mary's Campus, London W2 1PG, UK
9 shared publications - Nicholas J. Talley
University of Newcastle, Australia
9 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- p. 1-10
Histological characteristics of the lower esophagus among persons with and without GERD in a general population
Gastroesophageal reflux disease (GERD) is one of our most common global health problems [1,2]. Globally, the estimated age-standardized prevalence of GERD, defined as heartburn and/or regurgitation...
- 9 October 2026
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- p. 1-10
Open AccessHistological characteristics of the lower esophagus among persons with and without GERD in a general population
Gastroesophageal reflux disease (GERD) is one of our most common global health problems [1,2]. Globally, the estimated age-standardized prevalence of GERD, defined as heartburn and/or regurgitation...
- Open Access
- 31 December 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (9) , 2173-2185
Oral Microbiome Dysbiosis Is Associated With Precancerous Lesions and Disorders of Upper Gastrointestinal Tract: A Population-Based Study
INTRODUCTION: Oral microbiota may contribute to the development of upper gastrointestinal (UGI) disorders. In this study, we evaluated the association between microbiota of saliva, subgingival, and buccal mucosa and UGI disorders, particularly precancerous lesions. We also aimed to identify which oral site have the greatest potential as biomarkers for the development of UGI cancers. METHODS: In this population-based study, 388 adults underwent upper endoscopy with biopsies for histopathological analysis. UGI symptoms were assessed using a validated questionnaire, and 16S rRNA gene sequencing characterized the microbiota in 380 saliva, 200 subgingival, and 267 buccal mucosa samples collected during endoscopy. RESULTS: Dysbiosis of the salivary microbiota was observed in subjects with gastroesophageal reflux symptoms (GERSs) alone, as well as in those with combined conditions such as GERS and esophagitis, or esophagitis and Barrett's esophagus. Significant microbial alterations were also found in individuals with several stomach disorders including Helicobacter pylori infection, chemical reactive gastritis, atrophic gastritis, and intestinal metaplasia. However, microbiota dissimilarity in subgingival and buccal mucosa samples was primarily associated with Barrett's esophagus or gastric atrophy. Among identified genera in saliva, the association between Prevotella and Fusabacterium and atrophic gastritis and intestinal metaplasia was notable. In subgingival samples, the link of Fretibacterium with Barrett's esophagus and Fusabacterium with gastric atrophy and intestinal metaplasia has also been found to be important. DISCUSSION: Dysbiosis of saliva microbiota is linked to a broad spectrum of UGI disorders. However, microbiota dysbiosis in subgingival and buccal mucosa sites is specifically associated with the premalignant conditions such as Barrett's esophagus and gastric atrophy. Among oral sites, the subgingival microbiota shows more potential as a infectious biomarker for UGI cancers.
- 31 December 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 120 (9) , 2173-2185
Open AccessOral Microbiome Dysbiosis Is Associated With Precancerous Lesions and Disorders of Upper Gastrointestinal Tract: A Population-Based Study
INTRODUCTION: Oral microbiota may contribute to the development of upper gastrointestinal (UGI) disorders. In this study, we evaluated the association between microbiota of saliva, subgingival, and buccal mucosa and UGI disorders, particularly precancerous lesions. We also aimed to identify which oral site have the greatest potential as biomarkers for the development of UGI cancers. METHODS: In this population-based study, 388 adults underwent upper endoscopy with biopsies for histopathological analysis. UGI symptoms were assessed using a validated questionnaire, and 16S rRNA gene sequencing characterized the microbiota in 380 saliva, 200 subgingival, and 267 buccal mucosa samples collected during endoscopy. RESULTS: Dysbiosis of the salivary microbiota was observed in subjects with gastroesophageal reflux symptoms (GERSs) alone, as well as in those with combined conditions such as GERS and esophagitis, or esophagitis and Barrett's esophagus. Significant microbial alterations were also found in individuals with several stomach disorders including Helicobacter pylori infection, chemical reactive gastritis, atrophic gastritis, and intestinal metaplasia. However, microbiota dissimilarity in subgingival and buccal mucosa samples was primarily associated with Barrett's esophagus or gastric atrophy. Among identified genera in saliva, the association between Prevotella and Fusabacterium and atrophic gastritis and intestinal metaplasia was notable. In subgingival samples, the link of Fretibacterium with Barrett's esophagus and Fusabacterium with gastric atrophy and intestinal metaplasia has also been found to be important. DISCUSSION: Dysbiosis of saliva microbiota is linked to a broad spectrum of UGI disorders. However, microbiota dysbiosis in subgingival and buccal mucosa sites is specifically associated with the premalignant conditions such as Barrett's esophagus and gastric atrophy. Among oral sites, the subgingival microbiota shows more potential as a infectious biomarker for UGI cancers.
- Open Access
- 20 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Author Correction: Repeated out-of-Africa expansions of Helicobacter pylori driven by replacement of deleterious mutations
- 20 March 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Open AccessAuthor Correction: Repeated out-of-Africa expansions of Helicobacter pylori driven by replacement of deleterious mutations
- Open Access
- 18 October 2022
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 127 (1)
Ulcerative colitis progression: a retrospective analysis of disease burden using electronic medical records
Background: Ulcerative colitis (UC) is a debilitating inflammatory bowel disease. Present knowledge regarding UC disease progression over time is limited. Objective: To assess UC progression to severe disease along with disease burden and associated factors. Methods: Electronic medical records linked with Swedish national health registries (2005–2015) were used to identify disease progression of UC. Odds of all-cause and disease-related hospitalization within 1 year were compared between patients with disease progression and those without. Annual indirect costs were calculated based on sick leave, and factors related to UC progression were examined. Results: Of the 1,361 patients with moderate UC, 24% progressed to severe disease during a median of 5.2 years. Severe UC had significantly higher odds for all-cause (OR [odds ratio] 1.47, 95% CI [confidence interval]: 1.12–1.94, P < 0.01) and UC-related hospitalization (OR 2.47, 95% CI: 1.76–3.47, P < 0.0001) compared to moderate disease. Average sick leave was higher in patients who progressed compared to those who did not (64.4 vs 38.6 days, P < 0.001), with higher indirect costs of 151,800 SEK (16,415 €) compared with 92,839 SEK (10,039 €) (P < 0.001), respectively. UC progression was related to young age (OR 1.62, 95% CI: 1.17–2.25, P < 0.01), long disease duration (OR 1.09, 95% CI: 1.03–1.15, P < 0.001), and use of corticosteroids (OR 2.49, 95% CI: 1.67–3.72, P < 0.001). Conclusion: Disease progression from moderate to severe UC is associated with more frequent and longer hospitalizations and sick leave. Patients at young age with long disease duration and more frequent glucocorticosteroid medication are associated with progression to severe UC.
- 18 October 2022
- Published by Uppsala Medical Society in Upsala Journal of Medical Sciences
- Vol. 127 (1)
Open AccessUlcerative colitis progression: a retrospective analysis of disease burden using electronic medical records
Background: Ulcerative colitis (UC) is a debilitating inflammatory bowel disease. Present knowledge regarding UC disease progression over time is limited. Objective: To assess UC progression to severe disease along with disease burden and associated factors. Methods: Electronic medical records linked with Swedish national health registries (2005–2015) were used to identify disease progression of UC. Odds of all-cause and disease-related hospitalization within 1 year were compared between patients with disease progression and those without. Annual indirect costs were calculated based on sick leave, and factors related to UC progression were examined. Results: Of the 1,361 patients with moderate UC, 24% progressed to severe disease during a median of 5.2 years. Severe UC had significantly higher odds for all-cause (OR [odds ratio] 1.47, 95% CI [confidence interval]: 1.12–1.94, P < 0.01) and UC-related hospitalization (OR 2.47, 95% CI: 1.76–3.47, P < 0.0001) compared to moderate disease. Average sick leave was higher in patients who progressed compared to those who did not (64.4 vs 38.6 days, P < 0.001), with higher indirect costs of 151,800 SEK (16,415 €) compared with 92,839 SEK (10,039 €) (P < 0.001), respectively. UC progression was related to young age (OR 1.62, 95% CI: 1.17–2.25, P < 0.01), long disease duration (OR 1.09, 95% CI: 1.03–1.15, P < 0.001), and use of corticosteroids (OR 2.49, 95% CI: 1.67–3.72, P < 0.001). Conclusion: Disease progression from moderate to severe UC is associated with more frequent and longer hospitalizations and sick leave. Patients at young age with long disease duration and more frequent glucocorticosteroid medication are associated with progression to severe UC.
- Open Access
- 9 June 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (1) , 79
Editorial: tobacco use in functional dyspepsia—another smoking gun? Authors' reply
- 9 June 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (1) , 79
Open AccessEditorial: tobacco use in functional dyspepsia—another smoking gun? Authors' reply
- 13 May 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (1) , 32-42
Role of smoking in functional dyspepsia and irritable bowel syndrome: three random population‐based studies
Summary: Background: It is uncertain if functional dyspepsia (FD) or irritable bowel syndrome (IBS) are linked to smoking, and smoking cessation is not part of the routine advice provided to these patients.Aim: To assess if smoking is an independent risk factor for FD and IBS.Methods: Three population‐based endoscopy studies in Sweden with 2560 community individuals in total (mean age 51.5 years, 46% male). IBS (14.9%), FD (33.5%), and associated symptoms were assessed using the validated abdominal symptom questionnaire, and smoking (17.9%) was obtained from standardised questions during a clinic visit. The effect of smoking on symptom status was analysed in an individual person data meta‐analysis using mixed effect logistic regression, adjusted for snuffing, age and sex.Results: Individuals smoking cigarettes reported significantly higher odds of postprandial distress syndrome (FD‐PDS) (OR 10‐19 cig/day = 1.42, 95% CI 1.04‐1.98 P = 0.027, OR ≥20 cig/day = 2.16, 95% CI 1.38‐3.38, P = 0.001) but not epigastric pain. Individuals smoking 20 or more cigarettes per day reported significantly higher odds of IBS‐diarrhoea (OR = 2.40, 95% CI 1.12‐5.16, P = 0.025), diarrhoea (OR = 2.01, 95%CI 1.28‐3.16, P = 0.003), urgency (OR = 2.21, 95%CI 1.41‐3.47, P = 0.001) and flatus (OR = 1.77, 95%CI 1.14‐2.76, P = 0.012) than non‐smokers. Smoking was not associated with IBS‐constipation or IBS‐mixed.Conclusion: Smoking is an important environmental risk factor for postprandial distress syndrome, the most common FD subgroup, with over a twofold increased odds of PDS in heavy smokers. The role of smoking in IBS‐diarrhoea, but not constipation, is also likely important.
- 13 May 2021
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 54 (1) , 32-42
Role of smoking in functional dyspepsia and irritable bowel syndrome: three random population‐based studies
Summary: Background: It is uncertain if functional dyspepsia (FD) or irritable bowel syndrome (IBS) are linked to smoking, and smoking cessation is not part of the routine advice provided to these patients.Aim: To assess if smoking is an independent risk factor for FD and IBS.Methods: Three population‐based endoscopy studies in Sweden with 2560 community individuals in total (mean age 51.5 years, 46% male). IBS (14.9%), FD (33.5%), and associated symptoms were assessed using the validated abdominal symptom questionnaire, and smoking (17.9%) was obtained from standardised questions during a clinic visit. The effect of smoking on symptom status was analysed in an individual person data meta‐analysis using mixed effect logistic regression, adjusted for snuffing, age and sex.Results: Individuals smoking cigarettes reported significantly higher odds of postprandial distress syndrome (FD‐PDS) (OR 10‐19 cig/day = 1.42, 95% CI 1.04‐1.98 P = 0.027, OR ≥20 cig/day = 2.16, 95% CI 1.38‐3.38, P = 0.001) but not epigastric pain. Individuals smoking 20 or more cigarettes per day reported significantly higher odds of IBS‐diarrhoea (OR = 2.40, 95% CI 1.12‐5.16, P = 0.025), diarrhoea (OR = 2.01, 95%CI 1.28‐3.16, P = 0.003), urgency (OR = 2.21, 95%CI 1.41‐3.47, P = 0.001) and flatus (OR = 1.77, 95%CI 1.14‐2.76, P = 0.012) than non‐smokers. Smoking was not associated with IBS‐constipation or IBS‐mixed.Conclusion: Smoking is an important environmental risk factor for postprandial distress syndrome, the most common FD subgroup, with over a twofold increased odds of PDS in heavy smokers. The role of smoking in IBS‐diarrhoea, but not constipation, is also likely important.
- Open Access
- 22 December 2020
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 12 (1) , e00296
Ileocolonic Histopathological and Microbial Alterations in the Irritable Bowel Syndrome: A Nested Community Case-Control Study
INTRODUCTION: Histopathological alterations in the ileum and colon in irritable bowel syndrome (IBS) are controversial, and normal values are poorly established. We hypothesized that changes in mucosal immune cells characterize IBS and key changes in immune composition are associated with the mucosa-associated microbiota (MaM). METHODS: A nested case-control study (48 IBS and 106 controls included) from 745 colonoscopy participants in a random population sample. Intraepithelial lymphocytes (IELs)/100 enterocytes and eosinophils/5 nonoverlapping high-power fields counted; mast cells identified by immunocytochemistry (CD117)/5 high-power fields. Paneth cells quantified per 5 crypts. 16S rRNA gene amplicon sequencing performed on available sigmoid MaM, n = 55 and fecal microbiota, n = 20. Microbiota profiles compared between samples with high and low IEL counts. RESULTS: IBS had increased IELs in the terminal ileum (relative risk ratio = 1.70, 95% confidence interval 1.08–2.76, P = 0.022 adjusted for age, sex, and smoking). Cecal IELs were increased in IBS—diarrhea (relative risk ratio = 2.03, 95% confidence interval 1.13–3.63, P = 0.017). No difference was observed in alpha diversity of MaM or fecal microbiota based on IEL count. There was no difference in beta diversity of the MaM according to IEL count in the terminal ileal (TI) (P = 0.079). High TI IEL counts associated with a significant expansion of the genus Blautia (P = 0.024) and unclassified Clostridiales (P = 0.036) in colon MaM. DISCUSSION: A modest but significant increase in IELs was observed in IBS vs. controls in a population-based setting. Subtle TI and cecal inflammation may play a pathogenic role in IBS but needs confirmation. Modest but discernible differences in the colonic MaM were seen according to TI IEL count but not IBS status.
- 22 December 2020
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 12 (1) , e00296
Open AccessIleocolonic Histopathological and Microbial Alterations in the Irritable Bowel Syndrome: A Nested Community Case-Control Study
INTRODUCTION: Histopathological alterations in the ileum and colon in irritable bowel syndrome (IBS) are controversial, and normal values are poorly established. We hypothesized that changes in mucosal immune cells characterize IBS and key changes in immune composition are associated with the mucosa-associated microbiota (MaM). METHODS: A nested case-control study (48 IBS and 106 controls included) from 745 colonoscopy participants in a random population sample. Intraepithelial lymphocytes (IELs)/100 enterocytes and eosinophils/5 nonoverlapping high-power fields counted; mast cells identified by immunocytochemistry (CD117)/5 high-power fields. Paneth cells quantified per 5 crypts. 16S rRNA gene amplicon sequencing performed on available sigmoid MaM, n = 55 and fecal microbiota, n = 20. Microbiota profiles compared between samples with high and low IEL counts. RESULTS: IBS had increased IELs in the terminal ileum (relative risk ratio = 1.70, 95% confidence interval 1.08–2.76, P = 0.022 adjusted for age, sex, and smoking). Cecal IELs were increased in IBS—diarrhea (relative risk ratio = 2.03, 95% confidence interval 1.13–3.63, P = 0.017). No difference was observed in alpha diversity of MaM or fecal microbiota based on IEL count. There was no difference in beta diversity of the MaM according to IEL count in the terminal ileal (TI) (P = 0.079). High TI IEL counts associated with a significant expansion of the genus Blautia (P = 0.024) and unclassified Clostridiales (P = 0.036) in colon MaM. DISCUSSION: A modest but significant increase in IELs was observed in IBS vs. controls in a population-based setting. Subtle TI and cecal inflammation may play a pathogenic role in IBS but needs confirmation. Modest but discernible differences in the colonic MaM were seen according to TI IEL count but not IBS status.
- Open Access
Large-scale association analyses identify host factors influencing human gut microbiome composition
To study the effect of host genetics on gut microbiome composition, the MiBioGen consortium curated and analyzed genome-wide genotypes and 16S fecal microbiome data from 18,340 individuals (24 cohorts). Microbial composition showed high variability across cohorts: only 9 out of 410 genera were detected in more than 95% samples. A genome-wide association study (GWAS) of host genetic variation in relation to microbial taxa identified 31 loci affecting microbiome at a genome-wide significant (P−8 ) threshold. One locus, the lactase ( LCT ) gene locus, reached study-wide significance (GWAS signal P=1.28×10 −20 ), and it showed an age-dependent association with Bifidobacterium abundance. Other associations were suggestive (1.95×10 −10 −8 ) but enriched for taxa showing high heritability and for genes expressed in the intestine and brain. A phenome-wide association study and Mendelian randomization identified enrichment of microbiome trait loci in the metabolic, nutrition and environment domains and suggested the microbiome has causal effects in ulcerative colitis and rheumatoid arthritis.
Open AccessLarge-scale association analyses identify host factors influencing human gut microbiome composition
To study the effect of host genetics on gut microbiome composition, the MiBioGen consortium curated and analyzed genome-wide genotypes and 16S fecal microbiome data from 18,340 individuals (24 cohorts). Microbial composition showed high variability across cohorts: only 9 out of 410 genera were detected in more than 95% samples. A genome-wide association study (GWAS) of host genetic variation in relation to microbial taxa identified 31 loci affecting microbiome at a genome-wide significant (P−8 ) threshold. One locus, the lactase ( LCT ) gene locus, reached study-wide significance (GWAS signal P=1.28×10 −20 ), and it showed an age-dependent association with Bifidobacterium abundance. Other associations were suggestive (1.95×10 −10 −8 ) but enriched for taxa showing high heritability and for genes expressed in the intestine and brain. A phenome-wide association study and Mendelian randomization identified enrichment of microbiome trait loci in the metabolic, nutrition and environment domains and suggested the microbiome has causal effects in ulcerative colitis and rheumatoid arthritis.
- 1 April 2020
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 18 (4) , 847-854.e1
Effects of Psychology and Extragastrointestinal Symptoms on Health Care Use by Subjects With and Without Irritable Bowel Syndrome
- 1 April 2020
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 18 (4) , 847-854.e1
Effects of Psychology and Extragastrointestinal Symptoms on Health Care Use by Subjects With and Without Irritable Bowel Syndrome
- Open Access
Compositional and functional differences of the mucosal microbiota along the intestine of healthy individuals
Gut mucosal microbes evolved closest to the host, developing specialized local communities. There is, however, insufficient knowledge of these communities as most studies have employed sequencing technologies to investigate faecal microbiota. This work used shotgun metagenomics of mucosal biopsies to explore the microbial communities compositions of terminal ileum and large intestine in 5 healthy individuals. Functional annotations and genome-scale metabolic modelling of selected species were then employed to identify local functional enrichments. While faecal metagenomics provided a good approximation of the average gut microbiome composition, mucosal biopsies allowed detecting the subtle variations of local microbial communities. Given their significant enrichment in the mucosal microbiota, we highlight the roles of Bacteroides species and describe the antimicrobial resistance biogeography along the intestine. We also detail which species, at which locations, are involved with the tryptophan/indole pathway, whose malfunctioning has been linked to pathologies including inflammatory bowel disease. Our study thus provides invaluable resources for investigating mechanisms connecting gut microbiota and host pathophysiology.
Open AccessCompositional and functional differences of the mucosal microbiota along the intestine of healthy individuals
Gut mucosal microbes evolved closest to the host, developing specialized local communities. There is, however, insufficient knowledge of these communities as most studies have employed sequencing technologies to investigate faecal microbiota. This work used shotgun metagenomics of mucosal biopsies to explore the microbial communities compositions of terminal ileum and large intestine in 5 healthy individuals. Functional annotations and genome-scale metabolic modelling of selected species were then employed to identify local functional enrichments. While faecal metagenomics provided a good approximation of the average gut microbiome composition, mucosal biopsies allowed detecting the subtle variations of local microbial communities. Given their significant enrichment in the mucosal microbiota, we highlight the roles of Bacteroides species and describe the antimicrobial resistance biogeography along the intestine. We also detail which species, at which locations, are involved with the tryptophan/indole pathway, whose malfunctioning has been linked to pathologies including inflammatory bowel disease. Our study thus provides invaluable resources for investigating mechanisms connecting gut microbiota and host pathophysiology.